Literature DB >> 7683884

Clinical pharmacokinetics of 5-fluorouracil. Influence of the biomodulating agents interferon, dipyridamole and folinic acid alone and in combination.

M J Czejka1, W Jäger, J Schüller, U Fogl, C Weiss, G Schernthaner.   

Abstract

The pharmacokinetics of the antimetabolite 5-fluorouracil (5FU, CAS 51-21-8) were investigated under the influence of the biomodulating agents folinic acid (FA), FA combined with dipyridamole (DPM), DPM, interferon-alpha-2b (IFN), and IFN combined with DPM. IFN as well as IFN/DPM cause an enormous increase of the 5FU plasma concentrations resulting in a statistically significant change of the pharmacokinetics. The mean initial plasma concentrations of 5FU are increased at about 143% under the influence of IFN and at 162% under the influence of IFN/DPM. Accordingly, the mean area under the concentration-time curve is elevated at 114% for IFN and at 184% for IFN/DPM. The volume of distribution (IFN - 39%, IFN/DPM - 38%) as well as the total body clearance (IFN - 30%, IFN/IFN - 44%) are lowered distinctly. In contrary, the coadministration of either FA or DPM or FA/DPM to 5FU does not lead to a significant change in the pharmacokinetic profile of 5FU, but also causes higher plasma concentrations. The present results indicate that the coadministration of biomodulators can lead to distinct changes of the 5FU kinetics, but must not be useful in each case.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683884

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  4 in total

1.  Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b.

Authors:  M J Czejka; J Schüller; C Weiss; S Bandak; B Meyer; D Simon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Oct-Dec       Impact factor: 2.441

Review 2.  Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors.

Authors:  J Levin; J Hohneker
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

3.  Influence of different doses of interferon-alpha-2b on the blood plasma levels of 5-fluorouracil.

Authors:  M J Czejka; J Schüller; W Jäger; U Fogl; C Weiss
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

Review 4.  Pharmacokinetic drug interactions with anticancer drugs.

Authors:  P M Loadman; M C Bibby
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.